• Sign In
  • FAQ
  • Create an Account
Currency
USD currency flagUSD
Toggle Nav
My Cart
Menu
Account
Settings
Currency
USD currency flagUSD

Angiogenesis

Items 101-150 of 1726

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. A11558
    SU-5402

    VEGFR/FGFR/EGFR inhibitor?€?

    SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively).
    Quick View
  2. A10242
    CP-724714

    HER2/ErbB2 inhibitor

    CP-724714 is an orally available, small molecule, potent HER-2 tyrosine kinase inhibitor that inhibits HER2 kinase (IC50 3.8 ng/ml) .
    Quick View
  3. A10662
    TAE684

    ALK Inhibitor

    TAE684 is a inhibitor of ALK and also a potent inhibitor of LRRK2 kinase activity (IC(50) of 7.8nM against wild-type LRRK2, 6.1nM against the G2019S mutant).
    Quick View
  4. A11051
    Dacomitinib (PF299804, PF299)

    EGFR inhibitor

    Dacomitinib (PF299804, PF299) is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4.

    Quick View
  5. A13044
    Poziotinib

    EGFR inhibitor

    Poziotinib is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.
    Quick View
  6. A12358
    A 83-01

    TGF-β/ALK5 inhibitor

    A83-01 is a selective inhibitor of the transforming growth factor-beta type I receptor ALK5, the Nodal receptor ALK4, and the nodal receptor ALK7
    Quick View
  7. A11411
    Dovitinib (TKI-258)

    RTK inhibitor

    Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
    Quick View
  8. A10119
    Bafetinib (INNO-406)

    Bcr-Abl inhibitor

    Bafetinib ((INNO-406) is a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
    Quick View
  9. A10362
    Erlotinib HCl

    EGFR inhibitor

    Erlotinib hydrochloride is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
    Quick View
  10. A10678
    OSI-420

    EGFR Inhibitor

    OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
    Quick View
  11. A10324
    DMXAA (ASA404, Vadimezan)

    Vascular Disrupting Agent (VDA)

    DMXAA (ASA404) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.
    Quick View
  12. A10012
    2-Methoxyestradiol

    Apoptotic, antiproliferative and antiangiogenic agent

    2-Methoxyestradiol is an apoptotic, antiproliferative and antiangiogenic agent. Induces p53-induced apoptosis via two pathways: activation of p38 and NF-κB; and activation of JNK and AP-1 leading to Bcl-2 phosphorylation.
    Quick View
  13. A10053
    Tyrphostin AG 879

    HER2 inhibitor

    Tyrphostin AG 879 is an inhibitor of the tyrosine kinase activity of nerve growth factor (NGF) TrkA.
    Quick View
  14. A10062
    Allitinib tosylate (AST-1306 TsOH, AST-6)

    EGFR inhibitor

    AST-6 is a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, inhibits tumor growth both in vitro and in vivo
    Quick View
  15. A10154
    BMS-794833

    c-Met inhibitor

    BMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
    Quick View
  16. A10162
    Brivanib alaninate (BMS-582664)

    VEGFR inhibitor

    Brivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
    Quick View
  17. A10198
    Dovitinib Dilactic acid (TKI258 Dilactic acid)

    RTK inhibitor

    Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
    Quick View
  18. A10210
    Chrysophanic acid (Chrysophanol)

    EGFR inhibitor

    Chrysophanic acid (Chrysophanol) blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.
    Quick View
  19. A10246
    CUDC-101

    HDAC inhibitor

    CUDC-101 is a novel compound which inhibits multiple targets, which is designed to inhibit HDAC, EGFR and Her2.
    Quick View
  20. A10248
    CYC116

    Aurora Kinase inhibitor

    Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
    Quick View
  21. A10286
    Daphnetin

    EGFR, PKA,PKC inhibitor

    Daphnetin is a coumarin analog that acts as an inhibitor of several protein kinases. It inhibits EGFR kinase (IC50 = 7.67 μM), PKA (IC50 = 9.33 μM), and PKC (IC50 = 25 μM), in vitro. The inhibition of EGFR kinase by daphnetin was competitive to ATP and non-competitive to the peptide substrate. Also acts as a potent antioxidant and anti-malarial agent.
    Quick View
  22. A10352
    ENMD-2076

    Aurora A / FLT3 Inhibitor

    ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.
    Quick View
  23. A10425
    Genistein

    EGFR inhibitor

    Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
    Quick View
  24. A10504
    KRN 633

    VEGFR Inhibitor

    KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ??? 10 μM).
    Quick View
  25. A10508
    KW-2449

    FLT3/FGFR/Bcr-Abl/Aurora Inhibitor

    KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
    Quick View
  26. A10514
    Lapatinib Ditosylate

    HER2 inhibitor

    Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
    Quick View
  27. A10587
    MGCD-265 analog

    c-Met inhibitor

    MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.
    Quick View
  28. A10608
    Motesanib Diphosphate (AMG-706)

    VEGFR inhibitor

    Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors.
    Quick View
  29. A10610
    MP470 (MP-470, Amuvatinib)

    RTK inhibitor

    MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.
    Quick View
  30. A10612
    Mubritinib (TAK 165)

    HER2/ErbB2 inhibitor

    Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 μM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5.
    Quick View
  31. A10654
    NPI-2358 (Plinabulin)

    Microtubule Inhibitor

    NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells.
    Quick View
  32. A10679
    OSI-930

    c-Kit/VEGFR Inhibitor

    OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.
    Quick View
  33. A10702
    PD153035 (HCl salt)

    EGFR inhibitor

    PD153035 is an extremely potent and specific inhibitor of the tyrosine kinase activity of EGFR.
    Quick View
  34. A10770
    R406 (Tamatinib)

    Syk Inhibitor

    R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.
    Quick View
  35. A10771
    R935788 (Fostamatinib disodium, R788)

    Syk Inhibitor

    R935788 (Fostamatinib disodium) is a potent orally available inhibitor of Syk that inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
    Quick View
  36. A10773
    RAF265 (CHIR-265)

    RAF/VEGFR Inhibitor

    RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor, which is to control or normalize VEGFR-2 along with the inhibition of B-raf and c-Raf mutation to prevent cancers.
    Quick View
  37. A10774
    Raf265 derivative

    RAF/VEGFR Inhibitor

    Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.
    Quick View
  38. A10827
    SB 525334

    ALK Inhibitor

    SB525334 is a selective inhibitor of transforming growth factor-β receptor I (ALK5, TGF-βRI) (IC50 = 14.3 nM). Inhibits TGF-β1-induced smad2/3 nuclear localization and TGF-βRI-induced mRNA expression in kidney cells
    Quick View
  39. A10887
    Tandutinib (MLN518)

    FLT3 Inhibitor

    Tandutinib (MLN518) inhibits the autophosphorylation of FLT3, c-KIT and PDGF receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.
    Quick View
  40. A10903
    Telatinib (BAY 57-9352)

    VEGFR-2 inhibitor

    Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.
    Quick View
  41. A10990
    WZ3146

    EGFR Inhibitor

    WZ3146 is an inhibitor of EGFR receptor kinase mutants carrying a mutation in an active site gatekeeper residue (T790M) and is much less potent against wild-type EGFR kinase.
    Quick View
  42. A10991
    WZ4002

    EGFR Inhibitor

    WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib.
    Quick View
  43. A10992
    WZ8040

    EGFR Inhibitor

    WZ8040 is a novel EGFR inhibitors that suppress the growth of EGFR-T790M-containing cell lines and inhibit EGFR phosphorylation.
    Quick View
  44. A11027
    Arry-380 analog

    HER2 Inhibitor

    ARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
    Quick View
  45. A11057
    XL647 (Tesevatinib)

    EGFR, HER2 and VEGFR inhibitor

    XL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
    Quick View
  46. A11082
    TG-101348 (Fedratinib, SAR302503)

    JAK2/FLT3 inhibitor

    TG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.
    Quick View
  47. A21533
    Pamufetinib (TAS-115)

    VEGFR/c-Met/HGFR inhibitor

    TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
    Quick View
  48. A21561
    PT-2385

    HIF-2α inhibitor

    PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM.
    Quick View
  49. A21583
    ENMD-2076 Tartrate

    multi-targeted kinase inhibitor

    ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
    Quick View
  50. A21661
    Almonertinib hydrochloride (HS-10296 hydrochloride)

    EGFR/T790M inhibitor

    HS-10296 hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor (EGFR)-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
    Quick View

Items 101-150 of 1726

Page
per page
Set Descending Direction
Shop By
Shopping Options
Category
Actions
  1. Inhibitor 1495items
  2. Antagonist 5items
  3. Activator 2items
  4. Modulator 1item
  5. Degrader 6items
  6. Inducer 1item
Target
  1. HDAC 1item
  2. HDAC1 1item
  3. HDAC2 1item
  4. HDAC3 1item
  5. HDAC4 1item
  6. HDAC5 1item
  7. HDAC6 1item
  8. HDAC7 1item
  9. HDAC8 1item
  10. HDAC9 1item
  11. HDAC10 1item
  12. EGFR/ErbB1/HER1 15items
  13. ErbB2/HER2 7items
  14. ErbB4/HER4 1item
  15. JAK1 3items
  16. JAK2 10items
  17. JAK3 7items
  18. Tyk2 3items
  19. STAT3 1item
  20. SYK 2items
  21. CDK2 2items
  22. FLT3 3items